drugset / Trial / NCT03712280
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
RandomizedParallel-groupOpen-labelTreatment
Summary
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.
Timeline
- Start
- 2018-12-01
- Primary completion
- 2020-07-14
- Completion
- 2020-07-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MNK6106 | Unknown | 2 g | Oral |
| Subject | MNK6106 | Unknown | 4 g | Oral |
| Comparator | Rifaximin | Other / unclassified | 550 mg | Oral |